Colombian Patent Office grants a patent protecting revolutionary genetic therapy against cancer
February 13 2018

We congratulate our clients Novartis AG and The Trustees of the University of Pennsylvania for the recent granting of a patent directed to an isolated chimeric antigen receptor (CAR).  This development is related to the drug recently approved by the FDA, Kymriah®, considered the first gene therapy against acute lymphoblastic leukemia (ALL) in children and young adults.  The FDA has stated that this gene therapy is revolutionary and historic, entering a new frontier in the treatment of diseases such as ALL affecting children.  This treatment is, without doubt, a step forward for innovation and immunotherapy.

Categories

Archive

Archives